Business · 18/03/2015Updated: 10/17/2026 · 1 min read
US FDA to Host Public Meeting on Alternative In Vitro Bioequivalence Pathways for Non-Systemically Absorbed Animal Drugs
The US FDA will host a public meeting to discuss alternative in vitro bioequivalence pathways that can reliably ensure in vivo bioequivalence of product performance and quality for non-systemically absorbed drug products intended for animals.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →